Current Assets

Cash Cash Equivalents And Short Term Investments

Roivant Sciences Cash Cash Equivalents And Short Term Investments increased by 3.3% to $4.53B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 12.0%, from $5.15B to $4.53B. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityVolatile
First reportedQ4 2015
Last reportedQ1 2026

How to read this metric

An increase suggests strong cash generation or successful capital raising, while a decrease may signal heavy investment or cash burn.

Detailed definition

The aggregate of cash, cash equivalents, and short-term marketable securities that can be readily converted into cash wi...

Peer comparison

Standard measure of total liquid financial resources across all sectors.

Metric ID: current_assets_cash_cash_equivalents_and_short_term_investments

Historical Data

7 periods
 Q1 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$6.49B$5.39B$5.15B$4.89B$4.50B$4.39B$4.53B
QoQ Change-17.1%-4.5%-5.0%-7.9%-2.6%+3.3%
YoY Change-24.8%-18.6%-12.0%
Range$4.39B$6.49B
CAGR-21.4%
Avg YoY Growth-18.4%
Median YoY Growth-18.6%

Frequently Asked Questions

What is Roivant Sciences's cash cash equivalents and short term investments?
Roivant Sciences (ROIV) reported cash cash equivalents and short term investments of $4.53B in Q4 2025.
How has Roivant Sciences's cash cash equivalents and short term investments changed year-over-year?
Roivant Sciences's cash cash equivalents and short term investments decreased by 12.0% year-over-year, from $5.15B to $4.53B.
What does cash cash equivalents and short term investments mean?
Total cash and easily sellable short-term investments.